- Report
- April 2026
- 180 Pages
Global
From €4203EUR$4,750USD£3,602GBP
- Report
- February 2026
- 148 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP
- Report
- April 2026
- 160 Pages
Global
From €2938EUR$3,320USD£2,517GBP
€3672EUR$4,150USD£3,147GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP
- Report
- October 2025
- 160 Pages
Global
From €2796EUR$3,160USD£2,396GBP
€3495EUR$3,950USD£2,995GBP
- Training
- September 2027
- 2 Days
Global
€1569EUR$1,835USD£1,299GBP
€1811EUR$2,118USD£1,499GBP
- Training
- March 2027
- 2 Days
Global
€1569EUR$1,835USD£1,299GBP
€1811EUR$2,118USD£1,499GBP
- Training
- October 2026
- 2 Days
Global
€1569EUR$1,835USD£1,299GBP
€1811EUR$2,118USD£1,499GBP
- Report
- May 2026
- 132 Pages
Global
From €4291EUR$4,850USD£3,677GBP
- Report
- May 2026
- 300 Pages
Europe
From €3423EUR$3,869USD£2,934GBP
- Report
- December 2025
- 1135 Pages
Global
€1631EUR$1,907USD£1,350GBP
- Report
- September 2025
- 393 Pages
Global
From €5254EUR$6,146USD£4,350GBP
- Report
- July 2026
- 575 Pages
Global
From €4246EUR$4,799USD£3,639GBP
- Report
- June 2026
- 209 Pages
Global
From €4246EUR$4,799USD£3,639GBP
- Report
- June 2026
- 77 Pages
Global
From €4246EUR$4,799USD£3,639GBP
- Report
- June 2026
- 260 Pages
Global
From €4246EUR$4,799USD£3,639GBP
- Report
- February 2026
- 100 Pages
Middle East, Africa, Global Middle East, Africa, Global
From €4246EUR$4,799USD£3,639GBP
- Report
- September 2025
- 1316 Pages
Global
From €1812EUR$2,119USD£1,500GBP
- Report
- September 2025
- 380 Pages
Global
From €4380EUR$4,950USD£3,753GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more